



WELCOME TO THE NCCN 2021 VIRTUAL BREAST CANCER CONGRESS

NCCN would like to thank the outstanding faculty who are presenting and all of you for attending this educational event. We hope you find the information presented useful to your practice, and we encourage you to attend future NCCN educational initiatives.

AGENDA	PAGE 2
ACCREDITATION INFORMATION	PAGES 3 – 7
SUPPORTING ORGANIZATIONS	PAGE 5
CLAIMING CREDIT	PAGE 7
DISCLOSURE INFORMATION	PAGES 8 – 10
FACULTY BIOGRAPHIES	PAGES 11 – 15



- 10:30 – 10:35 AM **Opening Remarks**
William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- 10:35 – 11:20 AM **Understanding/Addressing Health Disparities
to Improve Breast Cancer Care**
Otis Webb Brawley, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- 11:25 AM – 12:10 PM **Genetic Testing in Patients with Breast Cancer:
Who Should Get Tested?**
Nadine M. Tung, MD
Beth Israel Deaconess Medical Center
- 12:10 – 12:25 PM **Break**
- 12:25 – 1:10 PM **Surgical and Radiation Treatment Updates to
Management of Breast Cancer, Including SABCS Updates**
Meena S. Moran, MD
Yale Cancer Center/Smilow Cancer Hospital
Doreen M. Agnese, MD
*The Ohio State University Comprehensive Cancer Center –
James Cancer Hospital and Solove Research Institute*
- 1:15 – 2:15 PM **Adjuvant and Neoadjuvant Therapies for Breast Cancer,
Including SABCS Updates**
Ingrid A. Mayer, MD, MSCI
Vanderbilt-Ingram Cancer Center
Erica M. Stringer-Reasor, MD
O'Neal Comprehensive Cancer Center at UAB
- 2:15 – 2:30 PM **Break**
- 2:30 – 3:00 PM **Breast Cancer in Young Adults:
Treatment Considerations and Supportive Care Options**
Ann H. Partridge, MD, MPH
Dana-Farber Cancer Institute
- 3:05 – 3:50 PM **Updates to the Systemic Treatment of
Metastatic Breast Cancer, Including SABCS Updates**
William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- 3:50 – 4:05 PM **Break**
- 4:05 – 4:35 PM **Management of Breast Cancer Brain Metastases**
Louis B. Nabors, MD
O'Neal Comprehensive Cancer Center at UAB
- 4:40 – 5:10 PM **Breast Cancer Survivors: Issues and Recommendations**
Amye J. Tevaarwerk, MD
University of Wisconsin Carbone Cancer Center
- 5:10 – 5:15 PM **Closing Remarks**



Program Overview

Breast cancer continues to be the second most common cause of cancer death in women in the United States. Results from numerous clinical trials continue to expand diagnostic and prognostic tools, therapeutic options, and supportive care strategies. It is important for health care professionals to remain up-to-date on current and emerging scientific data to make evidence-based treatment decisions and to provide optimal care for patients with breast cancer.

The *NCCN 2021 Virtual Breast Cancer Congress with Updates from the 2020 San Antonio Breast Cancer Symposium (SABCS)* will provide expert insights on the current standard of care for patients with breast cancer and include the latest clinical research updates from the *2020 SABCS* to assist clinicians in formulating breast cancer management strategies.

Intended Audience

This educational program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with breast cancer.

Learning Objectives

Following this program, participants should be able to:

Overall Congress Objectives

- Summarize the current standards of oncology care, key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), and clinical research updates from the *2020 SABCS*, and integrate appropriate strategies into clinical practice to optimize the management of patients with breast cancer and improve patient outcomes.
- Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of patients with breast cancer.

Understanding/Addressing Health Disparities to Improve Breast Cancer Care

- Review the diverse spectrum of socioeconomic issues contributing to disparities in access to and delivery of breast cancer care.
- Describe the effect of tumor biology and genetics on breast cancer risk and outcomes of treatment.
- Apply methods and strategies that provide equitable access to timely and high-quality breast cancer care to clinical practice.

Genetic Testing in Patients with Breast Cancer: Who Should Get Tested?

- Identify genes that are associated with an increased risk of hereditary breast cancer.
- Review current genetic testing criteria for patients with breast cancer.
- Recognize the challenges associated with genetic testing for patients with breast cancer.



Surgical and Radiation Treatment Updates to Management of Breast Cancer, Including SABCS Updates

- Develop an evidence-based approach for the surgical management of the axilla in patients with early stage breast cancer.
- Individualize radiation therapy recommendations based on patient and tumor characteristics.
- Discuss new and emerging data in the management of patients with early stage breast cancer and integrate key findings into clinical practice.

Adjuvant and Neoadjuvant Therapies for Breast Cancer, Including SABCS Updates

- Compare and contrast data on the clinical safety and efficacy of neoadjuvant regimens in early stage breast cancer.
- Recognize key patient and clinical factors that influence selection of systemic adjuvant therapy.
- Discuss clinical data of new and emerging supportive care interventions to enhance shared decision-making and improve quality of life of patients undergoing neoadjuvant/adjuvant chemotherapy.

Breast Cancer in Young Adults: Treatment Considerations and Supportive Care Options

- Review the breast cancer risk factors and tumor characteristics unique to the adolescent and young adult (AYA) population.
- Compare and contrast the various treatment modalities for the management of breast cancer in young adults.
- Recognize the supportive care issues unique to the AYA population and manage patients accordingly.

Updates to the Systemic Treatment of Metastatic Breast Cancer, Including SABCS Updates

- Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on hormone- and HER2-receptor status.
- Review the current therapeutic approaches for triple negative metastatic breast cancer.
- As appropriate, incorporate new and emerging therapeutic options into the management of patients with metastatic breast cancer.

Management of Breast Cancer Brain Metastases

- Recognize the frequency of brain metastases in patients with breast cancer and presenting signs and symptoms of metastases.
- Review the efficacy and potential effects on cognitive function and quality of life related to local treatment of brain metastases, such as stereotactic radiosurgery and whole brain radiation therapy.
- Identify systemic therapy options for patients with brain metastases from breast cancer.

Breast Cancer Survivors: Issues and Recommendations

- List some of the more common physical, psychological, and psychosocial late and long-term effects associated with breast cancer and its treatment.
- Counsel breast cancer survivors about healthy lifestyle changes that can decrease the risks for many late and long-term effects.
- Develop strategies for screening and management of common late and long-term effects in breast cancer survivors.



Program Supporters

This activity is supported by educational grants from:

- AstraZeneca
- Biotheranostics, Inc.
- Daiichi Sankyo
- Gilead Sciences
- Novartis
- Pfizer
- Puma Biotechnology

Supported by an independent educational grant from Merck & Co., Inc.

This program is supported by an independent medical education grant from Bristol Myers Squibb.

Supporter list updated February 2, 2021.

Accreditation Statements

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

NCCN designates this live activity for a maximum of 6.25 *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

NCCN designates this educational activity for a maximum of 6.25 contact hours.

Pharmacists

NCCN designates this knowledge-based continuing education activity for 6.25 contact hours (0.625 CEUs) of continuing education credit. **UAN: JA4008196-0000-21-001-L01-P**

Physician Assistants

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 6.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



Accreditation Statements (cont.)

American Board of Internal Medicine Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.25 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Continuing Certification (CC)

This activity has been registered to offer credit in the American Board of Pathology's (ABPath) Continuing Certification program. Successful completion of this CME activity enables the participant to earn up to 6.25 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Medical Specialties (MOC)

*Through the American Board of Medical Specialties ("ABMS") MOC Initiative to create a wide array of Maintenance of Certification ("MOC") Activities through the ABMS MOC Directory, the **NCCN 2021 Congress Series: Breast Cancer** has met the MOC requirements as a **MOC Part II CME Activity** (apply toward general CME requirement) by the following ABMS Member Boards:*

MOC Part II CME Activity

Medical Genetics and Genomics
Pathology
Radiology



Requirements for Receiving CE Credit

Before or during the congress, please ensure that you have an NCCN account and will receive the correct type of credit.

1. Log in at www.NCCN.org.
 - If you do not have an NCCN account, click “Sign up here” to create one for free.
2. Click “Profile” in the left side menu.
3. Verify that your User Type matches the type of credit you will claim:
 - Physician/Surgeon/Oncologist = physician credits; ABIM MOC points, if applicable*
 - Pharmacist = pharmacist CEUs**
 - Nurse Practitioner = nurse contact hours; physician credits
 - Clinical Nurse Specialist = nurse contact hours
 - Nurse/Oncology Nurse = nurse contact hours
 - Case Manager (Nurse) = nurse contact hours
 - All other user types = certificate of participation
4. Scroll down and click “Save” if you make any changes.

Within 5 business days of this educational activity, you will receive an email with instructions on how to complete the CE requirements online through NCCN’s Continuing Education Portal (<http://education.nccn.org/breast2021>).

Within 30 days of the activity, you must:

- Attend the activity.
- Complete the immediate post-test.
- Complete the evaluation.
- Claim your credits.

You will be able to view/print your certificate online once all requirements have been met.

***Physicians claiming ABIM/ABPath MOC Points:** MOC points are reported to ABIM and ABPath once you have completed the post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your ABIM/ABPath learner ID and date of birth. Your credit cannot be reported without this information.

****Pharmacists:** You must complete the post-test and evaluation within 30 days of the activity. Continuing pharmacy education credit is reported to the CPE Monitor once you have completed these post-test and evaluation and claimed your credits. Before completing these requirements, be sure your NCCN profile has been updated with your NAPB e-profile ID and date of birth. Your credit cannot be reported without this information.

If you have any questions, please email education@nccn.org.



NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME's Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics).

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals' relationships with external entities is available upon request.

Definitions

NCCN continuing education considers financial relationships to create a "conflict of interest" when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers "relevant financial relationships" as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.



Faculty Disclosures

The faculty listed below discloses **no relevant** financial relationships:

Doreen M. Agnese, MD
Meena S. Moran, MD
Ann H. Partridge, MD, MPH
Amye J. Tevaarwerk, MD

The faculty listed below discloses the following **relevant** financial relationships:

Otis Webb Brawley, MD
Genentech, Inc.: Scientific Advisor
PDX Biosciences: Board Member

William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
MacroGenics, Inc.: Scientific Advisor
Pfizer Inc.: Scientific Advisor
Roche Laboratories, Inc./Genentech, Inc.: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor

Ingrid A. Mayer, MD, MSCI
AbbVie Inc.: Consulting Fee
AstraZeneca Pharmaceuticals LP: Consulting Fee; Honoraria
Genentech, Inc.: Grant/Research Support; Consulting Fee; Honoraria
GlaxoSmithKline: Consulting Fee
Immunomedics, Inc.: Consulting Fee
Novartis Pharmaceuticals Corporation: Grant/Research Support; Consulting Fee; Honoraria
Lilly: Consulting Fee
MacroGenics, Inc: Consulting Fee
Pfizer Inc.: Grant/Research Support
Puma Biotechnology: Consulting Fee
Seattle Genetics, Inc.: Consulting Fee

Louis B. Nabors, MD
BTG: Scientific Advisor
Karyopharm Therapeutics: Scientific Advisor

Erica M. Stringer-Reasor, MD
Curio Science: Product/Speakers Bureau
Immunomedics, Inc.: Scientific Advisor
Lilly: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Susan G. Komen: Grant/Research Support
The V Foundation: Grant/Research Support

Nadine M. Tung, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Myriad Genetic Laboratories, Inc.: Grant/Research Support



NCCN Staff Disclosures

The NCCN Activity Planning staff listed below discloses **no relevant** financial relationships:

Mike Abrams; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Lisa Perfidio, MS; Shannon Ryan, CMP; Kathy Ann Smith, CHCP; Sarah Weinstein

The NCCN Clinical staff listed below discloses **no relevant** financial relationships:

Mary Ann Bergman; Jennifer L. Burns, BS; Susan D. Darlow, PhD; Mary A. Dwyer, MS, CGC; Deborah A. Freedman-Cass, PhD; Giby V. George, MD; Rashmi Kumar, PhD; Nicole R. McMillian, MS, CHES; Dorothy A. Shead, MS



Doreen M. Agnese, MD, is a surgical oncologist, clinical geneticist and researcher at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.

Dr. Agnese earned her medical degree from University of Medicine & Dentistry of New Jersey, where she also completed a research fellowship and general surgery residency. She completed fellowships in surgical oncology and human cancer genetics at The Ohio State University.

Dr. Agnese specializes in treating breast cancer patients. She not only provides surgical care as a member of the multidisciplinary team, but also provides risk assessment, counseling and risk reduction to those at increased risk. Dr. Agnese's research focuses on all aspects of surgical oncology and cancer genetics, particularly breast tumors associated with the inheritable BRCA1 and BRCA2 genes.

Dr. Agnese is committed to educating the next generation of surgeons and oncologists. She teaches and mentors young physicians, plans extension and continuing education programs, and trains students in genetic counseling. Dr. Agnese has been extensively published, both in research and teaching. She has been named to several Castle Connolly lists, including "Regional Top Doctors," "Exceptional Women in Medicine," and was rated in the top 10 percent of physicians in the nation for patient satisfaction.

Dr. Agnese serves as the chair of the Committee on Applicants for the American College of Surgeons (Ohio District #3). She also serves as a member of the NCCN Breast Cancer Panel and serves on the editorial board of the Cancer Genetics PDQ (breast and gynecologic cancers working group) for the NCI.

Otis Webb Brawley, MD, is Professor of Oncology at the Johns Hopkins University School of Medicine, and 39th Bloomberg Distinguished Professor at Johns Hopkins. He leads a broad interdisciplinary research effort of cancer health disparities at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, working to close racial, economic, and social disparities in the prevention, detection and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland as the Kimmel Cancer Center's Associate Director for Community Outreach and Engagement.

Dr. Brawley earned his medical degree from the University of Chicago Pritzker School of Medicine. He completed an internal medicine residency at University Hospitals of Cleveland, Case-Western Reserve University, and a fellowship in medical oncology at the National Cancer Institute.

Dr. Brawley is a globally-recognized expert in cancer prevention and control. He has worked to reduce over-screening of medical conditions, which has revolutionized patient treatment by increasing quality of life and reducing health disparities.

Dr. Brawley's research focuses on developing cancer screening strategies and ensuring their effectiveness. He has championed efforts to decrease smoking and implement other lifestyle risk reduction programs, as well as to provide critical support to cancer patients and concentrate cancer control efforts in areas where they could be most effective.

Dr. Brawley is a member of the National Academy of Medicine, and recently received the Martin D. Abeloff Award for Excellence in Public Health and Cancer Control from the Maryland State Council of Cancer Control. The award, named after the former Director of the Kimmel Cancer Center, was established to recognize advancements made in cancer control practices that influenced the field of public health on a statewide, national, or global scale.



William J. Gradishar, MD, is the Betsy Bramsen Professor of Breast Oncology, Professor of Medicine, and Chief in the Division of Hematology and Medical Oncology at the Feinberg School of Medicine at Northwestern University. Dr. Gradishar also serves as Deputy Director for the Clinical Network of the Robert H. Lurie Comprehensive Cancer Center, where he also acts as Director of the Maggie Daley Center for Women's Cancer Care. Additionally, he has served as Chair of the Annual Lynn Sage Comprehensive Breast Cancer Symposium since its inception.

Dr. Gradishar earned his medical degree from the University of Illinois Abraham School of Medicine. He later completed a residency and chief residency in internal medicine at Michael Reese Hospital and Medical Center and a fellowship in medical oncology at the University of Chicago. He is board certified in internal medicine and medical oncology.

Dr. Gradishar specializes in the area of breast cancer therapeutics, with a focus on new endocrine therapy, chemotherapy, and biologic agents. He is a Fellow of the American College of Physicians and the American Society of Clinical Oncology (ASCO). He also is a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors. Additionally, Dr. Gradishar serves as a consultant to the FDA's Oncology Drug Advisory Committee.

Dr. Gradishar is past-Chair of several ASCO committees, including the Nominating Committee, the Professional Development Committee, the Oncology Training Program Committee, and the Communications Committee. He also previously served on the Committee on Cancer for the American College of Surgeons, as well as numerous study sections, including NIH, NCI, ACS, Komen, and the Alberta Cancer Board. In addition to his professional memberships, Dr. Gradishar is an editorial board member for numerous journals, including *Journal of Clinical Oncology*, *Oncology*, *Clinical Breast Cancer*, *Journal Watch*, *European Journal of Clinical and Medical Oncology*, *Clinical Cancer Research*, and *JNCCN—Journal of the National Comprehensive Cancer Network*.

Dr. Gradishar is Chair of the NCCN Breast Cancer Panel and a member of the NCCN Breast Cancer Risk Reduction Panel. He also has participated on several committees for the NCCN Oncology Research Program.

Ingrid A. Mayer, MD, MSCI, is Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt-Ingram Cancer Center (VICC), where she currently serves as Leader of the VICC Breast Cancer Program.

Dr. Mayer obtained her medical degree from the Federal University of São Paulo in Brazil. Thereafter, she completed her post-graduate training, including an internship, residency, chief-residency, and hematology/medical oncology fellowship, at the University of Illinois at Chicago. After joining Vanderbilt University Medical Center and VICC, Dr. Mayer completed the Master of Science in Clinical Investigation Program at Vanderbilt University School of Medicine.

During her tenure at VICC, Dr. Mayer has received grant funding from National Cancer Institute, the Breast Cancer Research Foundation, Stand Up To Cancer, and Susan G. Komen®, allowing her to focus her research endeavors on 1) the identification of targetable pathways in breast cancer; 2) ErbB signaling and endocrine therapy resistance in estrogen receptor positive (ER+) breast cancers; 3) PI3K signaling and endocrine therapy resistance in ER+ breast cancers; 4) chemotherapy resistance in triple negative breast cancers; and 5) biomarker prediction of treatment response in human breast cancers. She has been a principal investigator on more than 80 breast cancer clinical trials, spanning from Phase I to Phase III trials. In 2018, Dr. Mayer was named a Komen Scholar for her leadership in breast cancer research.



(Ingrid A. Mayer, MD, MSCI, cont.) In view of her clinical trial experience, Dr. Mayer was appointed as Chair of the VICC Data Safety and Monitoring Committee in 2010. Nationally, Dr. Mayer is an active member of the ECOG-ACRIN Breast Core Committee. She also is highly involved with the Translational Breast Cancer Research Consortium (TBCRC) and serves on the TBCRC Steering Committee. For the past 10 years, she has served as Co-Chair of the TBCRC Endocrine Resistance Working Group.

Dr. Mayer is a member of the NCCN Breast Cancer Panel and contributes to the NCCN Oncology Research Program.

Meena S. Moran, MD, is Professor of Therapeutic Radiology at Yale School of Medicine and Director of the Yale Breast Radiotherapy Program for the Yale New Haven Hospital Healthcare System.

Dr. Moran earned her medical degree from Cornell University Medical College. She completed her post-graduate training at Columbia University's St. Luke's – Roosevelt Hospital and Yale New Haven Hospital. Dr. Moran is board-certified in radiation oncology.

Dr. Moran's clinical research focuses on identifying clinical, pathological, and molecular factors that may predict local-regional relapse after breast conserving surgery. Her other research interests include radiation therapy in patients with breast cancer, examining ethnic variations in breast cancer, and investigating radiation techniques. Additionally, she has published in furthering quality improvement, guidelines, and standards in breast health care delivery.

Dr. Moran has been actively involved with many professional organizations and has had leadership roles for the American Society of Clinical Oncology (ASCO), the American Society of Radiation Oncology (ASTRO), Society for Surgical Oncology (SSO), the National Accreditation for Program for Breast Centers (NAPBC), the American Board of Radiology (ABR). She co-chaired the SSO/ASTRO margins guidelines for breast conservation therapy for both invasive cancers and for DCIS.

Additionally, as a founding board member for the NAPBC through the American College of Surgeons, Dr. Moran worked to establish national standards for breast center programs across the country and was involved in the development of the NAPBC's pilot program for surveying centers for accreditation. She also has been on numerous journals' editorial boards including Journal of Clinical Oncology and The Breast Journal, has served as Associate Senior Breast Editor for International Journal of Radiation Therapy, Biology, Physics for 5 years, and is currently an Associate Editor for Breast Cancer Research & Treatment.

Dr. Moran has been a member of the NCCN Breast Cancer Panel since 2015 as a radiation specialist, and is currently serving as the Breast Panel's Vice Chair.

Louis Burt Nabors, MD, is Vice-Chairman of Neurology, Professor, and Director of the Neuro-Oncology Program at the University of Alabama at Birmingham Comprehensive Cancer Center.

Dr. Nabors earned his medical degree from the University of Tennessee. He later completed an internship in medicine at the National Naval Medical Center in Bethesda, Maryland, as well as a residency in neurology and a fellowship in neuro-oncology at the University of Alabama at Birmingham. He served as a United States Navy Flight Surgeon on active duty from 1991–1995 and reserves from 1995–2002.

Dr. Nabors research examines primary brain tumors, specifically focusing on the role of post-transcriptional regulation of gene expression, the acquisition and post-processing of magnetic resonance imaging data, and early phase clinical evaluation of novel cancer therapies.



(Louis Burt Nabors, MD, cont.) Dr. Nabors is a member of the American Academy of Neurology, the American Society of Clinical Oncology, the American Neurological Association, and the Society for Neuro-Oncology. He also has served as an ad-hoc reviewer for multiple scientific journals and has authored or co-authored numerous journal articles, abstracts, and book chapters. He also serves on the editorial board for *Neuro Oncology*. Dr. Nabors is Chair of the NCCN Central Nervous Systems Cancers Panel and an editorial board member for *JNCCN—Journal of the National Comprehensive Cancer Network*.

Ann H. Partridge, MD, MPH, is Vice Chair of Medical Oncology, Founder and Director of the Program for Young Women with Breast Cancer, Director of the Adult Survivorship Program, and Senior Physician at Dana-Farber Cancer Institute. She is also Professor of Medicine at Harvard Medical School.

Dr. Partridge earned her medical degree from Weill Medical College of Cornell University. She completed a residency in internal medicine at University of Pennsylvania School of Medicine, and a hematology/oncology fellowship at Dana-Farber/Partners CancerCare. She received an MPH from Harvard School of Public Health. Dr. Partridge is board certified in medical oncology, internal medicine, and hematology.

Dr. Partridge's research focuses on psychosocial and medical outcomes of patients with cancer with a particular focus on young women with breast cancer and cancer survivorship issues. Current projects include a large prospective cohort study of young women with breast cancer, a randomized trial evaluating the efficacy of an educational and supportive care program for young women with breast cancer, evaluations of age, race and outcomes in breast cancer survivors, decision-making and quality of life in a large cooperative group breast cancer trial, and studies to improve understanding of and optimize cancer survivorship care.

Erica M. Stringer-Reasor, MD, is Assistant Professor of Medicine in the division of hematology and oncology at the University of Alabama at Birmingham.

Dr. Stringer-Reasor earned her medical degree from University of South Alabama. She completed an internship at Tulane University and residency at Baptist Health System. She was dual-trained in medical hematology/oncology and clinical pharmacology at pharmacogenomics at the University of Chicago. Dr. Stringer-Reasor is board certified in internal medicine, medical oncology, and hematopathology.

Dr. Stringer-Reasor's research interests include clinical trial design, pharmacokinetics (PK)/pharmacodynamics (PD) analysis, drug development, and patient care. Her focus remains in translational research specifically in the treatment of highly aggressive women's malignancies, in which she has received grant funding from the American Society of Clinical Oncology, Susan G. Komen, V Foundation, and the Breast Cancer Research Foundation of Alabama to explore novel therapies.

Dr. Stringer-Reasor serves as a member of the Translational Breast Cancer Research Consortium (TBCRC), Eastern Cooperative Oncology Group (ECOG), American Society of Clinical Oncology (ASCO), American Society for Clinical Pharmacology and Therapeutics (ASCPT), American Association for Cancer Research (AACR), Southwest Oncology Group (SWOG), and the International Gynecologic Cancer Society (IGCS). Dr. Stringer-Reasor currently serves as a member of the NCCN Breast Cancer Panel.



Amye J. Tevaarwerk, MD, is Associate Professor in the Division of Hematology, Medical Oncology and Palliative Care within the Department of Medicine at University of Wisconsin School of Medicine and Public Health.

Dr. Tevaarwerk earned her medical degree from Washington University School of Medicine. She completed a residency in internal medicine at Barnes-Jewish Hospital, and a fellowship in Medical Oncology at University of Wisconsin.

Dr. Tevaarwerk's research focuses on health and employment concerns as they relate to cancer survivorship. Her research team leverages systems-engineering approaches to better integrate existing health IT tools (such as the EHR and patient portals) with clinical workflows, with the goal of improving care processes such as communication, collaboration and care coordination between survivors and healthcare providers. Her dual roles as Director of the Survivorship Program at the UW Carbone Cancer Center and member of the UW Health Physicians Informatics Team illustrate this approach. She also serves as a member of the NCCN Survivorship Panel and NCCN EHR Oncology Advisory Group, as well as Epic's Oncology Steering Board.

Dr. Tevaarwerk's clinical specialty is breast oncology, and she is a member of the Breast and Palliative Disease-Oriented Teams, through which multiple clinical trials are helping to find both better treatments and supportive care approaches for those with cancer. She is a member of the ECOG-ACIRN Breast Cancer Committee.

Nadine M. Tung, MD, is Director of the Cancer Genetics and Prevention Program at Beth Israel Deaconess Medical Center (BIDMC), which she established in 1997 to evaluate patients and families with hereditary cancer syndromes. She leads the breast medical oncology section at BIDMC and is a member of the Dana-Farber Harvard Cancer Center, as well as Professor of Medicine at Harvard Medical School.

Dr. Tung earned her medical degree from Harvard Medical School. She completed a residency and fellowship at Beth Israel Deaconess Medical Center. Dr. Tung is board certified in medical oncology.

Dr. Tung's research focuses on hereditary causes of breast cancer, as well as effective strategies for breast cancer prevention and treatment. Much of her research has focused on women with BRCA1 and BRCA2 mutations, studying the genetic and environmental factors that influence cancer development, the biology and prognosis of the breast cancers they develop, and the optimal treatment. Through BRCF, she ran a multi-center, national trial evaluating whether cisplatin is superior to standard chemotherapy for women with BRCA1/2 mutations and newly diagnosed breast cancer. Dr. Tung also focuses on identifying other inherited gene mutations that predispose to breast cancer. She has led several trials evaluating PARP inhibitors in patients with hereditary breast cancer and breast cancers with homologous recombination deficiency. Other areas of her research include evaluating the prognosis and optimal treatment of triple negative breast cancer.

Dr. Tung has served on the Editorial Board of the Journal of Clinical Oncology, and the American Society of Clinical Oncology's Cancer Prevention Committee and Cancer Genetics Subcommittee.